Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
- Completed enrollment for SAT-3247 in Duchenne muscular dystrophy (DMD) in the first three (of five) single-ascending dose (SAD) cohorts with no safety concerns and initiated enrollment of first...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
- Analysis showed improvement in muscle morphology and increased levels of regeneration in muscle groups, including the diaphragm, quadriceps, and calf - No adverse events and no significant...
- The first healthy volunteer has been dosed in the first component of the Phase 1 study - Initial safety and pharmacokinetic data expected in Q4 2024 - Initiation of the second component of...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
Dosing of first participant in a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech...
- Updated data in a canine model of Duchenne muscular dystrophy (DMD) show further increased improvement in muscle force over baseline of 195% at four-month point - Receipt of Orphan Drug and...
– SAT-3247 is a proprietary, oral small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle which is lost in Duchenne muscular dystrophy (DMD) – DMD is a...
– Investigational New Drug (IND) enabling preclinical and toxicology studies successfully completed – Initiation of a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.08 | -9.63855421687 | 0.83 | 0.85 | 0.67 | 111964 | 0.80028132 | CS |
| 4 | 0 | 0 | 0.75 | 0.9 | 0.67 | 119098 | 0.83104853 | CS |
| 12 | 0.22 | 41.5094339623 | 0.53 | 0.9 | 0.45 | 131415 | 0.68572591 | CS |
| 26 | 0.27 | 56.25 | 0.48 | 0.9 | 0.45 | 91490 | 0.62797361 | CS |
| 52 | 0.13 | 20.9677419355 | 0.62 | 0.9 | 0.38 | 82552 | 0.60781725 | CS |
| 156 | 0.13 | 20.9677419355 | 0.62 | 0.9 | 0.38 | 82552 | 0.60781725 | CS |
| 260 | 0.13 | 20.9677419355 | 0.62 | 0.9 | 0.38 | 82552 | 0.60781725 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
